A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women

Epidemiology and Infection

Volumn 117, Issue 3, 1996, Pages 519-524

  Brugha, R ^a   Ramsay, M ^a   Forsey, T ^b   Brown, D ^c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH CARE POLICY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEASLES; MEASLES VACCINATION;

EID: 0029753694     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268800059203     Document Type: Article

References (34)

1. Black FL, Berman LL, Borgnono JM, et al. Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody. Am J Epidemiol 1986; 124: 442-52.
2. Wilkins J, Wehrle PF. Evidence for the re-instatement of infants 12 to 14 months of age into routine measles immunization programs. Am J Dis Child 1978; 132: 164-6.
3. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: Mechanism of vaccine failure. J Pediatr 1977; 91: 715-8.
4. Krugman S, Giles JP, Friedman H, Stone S. Studies on immunity to measles. J Pediatr 1965; 66: 471.
5. ACIP. Measles Prevention: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1989; 38: S9 (1-18).
6. Guidelines for measles control in Canada. Canada Dis Wkly Rep 1991; 17: 35-9.
7. Department of Health. Immunisation against Infectious Disease. London: HMSO, 1992.
8. CDC. Recommended Childhood Immunization Schedule-United States, January 1995. MMWR 1995; 43: 959-60.
9. Lennon JL, Black FL. Maternally derived measles immunity in era of vaccine-protected mothers. J Pediatr 1986; 108: 671-6.
10. Pabst HF, Donald WS, Marysysk RG, Carson MM, Chui LW-L, Joffres MR, Grimsrud KM. Reduced measles immunity in infants in a well-vaccinated population. Pediatr Infect Dis J 1992; 11: 525-9.
11. Yeager AS, Harvey B, Crosson FJ, Da vis JH, Ross LA, Halonen PE. Need for measles revaccination in adolescents: Correlation with birth date prior to 1972. J Pediatr 1983; 102: 191-5.
12. Kakica MA, Venezia RA, Miller J, Hughes PA, Lepow ML. Measles antibodies in women and infants in the vaccine era. J Med Virol 1995; 45: 227-9.
13. Jenks PJ, Caul EO, Roome APCH. Maternally derived measles immunity in children of naturally infected and vaccinated mothers. Epidemiol Infect 1988; 101: 473-6.
14. Carson MM, Spady DW, Albrecht P, et al. Measles vaccination of infants in a well-vaccinated population. Pediatr Infect Dis J 1995; 14: 17-22.
15. Person MJ, Whybin LR, Robertson PW. Pilot study of measles immunity in infants aged four to six months. Commun Dis Intell 1995; 19: 30-1.
16. Kamat M, Pyati S, Pildes RS, et al. Measles antibody titres in early infancy. Arch Pediatr Med 1994; : 694-8.
17. Chui LWL, Maryusyk RG, Pabst HF. Measles virus specific antibody in infants in a highly vaccinated society. J Med Virol 1991; 33: 199-204.
18. Medical Research Council. Measles Vaccine Committee. Vaccination against measles: a clinical trial of live measles vaccine given alone and live measles vaccine preceded by killed vaccine. BMJ 1966; i: 441-6.
19. Cremer NE, Cossen CK, Shell G, Diggs J, Gallo D, Schmidt NJ. Enzyme immunoassay versus plaque neutralisation and other methods for determination of immune status to measles and varicella-zoster viruses and versus compliment fixation for serodiagnosis of infections with these viruses. J Clin Micro 1983; 21: 869-74.
20. Grist NR, Ross CA, Bell EJ. Diagnostic methods in clinical virology. Oxford : Blackwell Scientific Publications, 1974.
21. Forsey T, Heath AB, Minor PB. The 1st International Standard for anti-measles serum. Biologicals 1991; 19: 237-41.
22. Albrecht P, Herrman K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralisation test. J Virol Meth 1981; 3: 251-60.
23. Mann GF, Allison MC, Copeland JA, Agostini CFM, Zuckermann AJ. A simplified plaque assay system for measles virus. J Biol Stand 1980; 8: 219-25.
24. Finney DJ. Probit analysis. Cambridge: Cambridge University Press, 1971.
25. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody : reevaluation of protective titres. J Infect Dis 1990; 162: 1036-42.
26. Burgess W, Garelick H, Mann GF, Tomkins A. Measurement of prevaccination antibody levels using a plaque inhibition assay to predict the optimum age for measles immunization : 12th International Congress for tropical medicine and malaria; abstract. Kager PA, Polderman AM, eds. Amsterdam: Exerpta medica 1988. (Excerpta Medica International Congress Series 810).
27. Wolynetz MS. Maximum likelihood estimation in a liners model from confined and censored normal data. Appl Stat 1979; 28: 195-206.
28. Ramsay M, Gay N, Miller E, Rush M, White J, Morgan-Capner P, Brown D. The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. Commun Dis Rep 1994; 4: R141-6.
29. Markowitz LE, Orenstein WA. Measles vaccines. Pediatr Clin N Am 1990; 37: 603-25.
30. Christenson B, Böttiger M. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994; 12: 129-33.
31. Shasby DM, Shope TC, Downs H, et al. Epidemic measles in a highly vaccinated population. N Engl J Med 1977; 296: 585.
32. Davis RM, Whitman ED, Orenstein WA, et al. A persistent outbreak of measles despite appropriate control measures. Am J Epidemiol 1987; 126: 438.
33. Department of Health Statistics Division. 1995; Form SBL 607, 1966-86; Form KC51, 1987-94.
34. Miller E. The new measles campaign. BMJ 1994; 309: 1102-3.